Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Michaelis Discusses the JAK2 Mutation in MPNs

Laura Michaelis, MD
Published: Wednesday, Sep 26, 2018



Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms (MPNs).

There are certain driver mutations in MPNs that have been established for a long time, Michaelis says. The percentage of patients with any given driver mutation is different in any of the 3 types of MPNs—polycythemia vera, essential thrombocythemia (ET), and myelofibrosis. Ever since the first mutation was described, questions have been asked as to why some patients act one way while others act another.

One of the factors that describes a patient’s later risk is the presence of a JAK2 mutation, Michaelis explains. Treatment is being changed based on the presence of JAK2, especially in ET. Decision-making for the treatment of these patients is much different now than it was 2 or 3 years again, says Michaelis, which she attributes to the understanding of the JAK2 mutation.


Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms (MPNs).

There are certain driver mutations in MPNs that have been established for a long time, Michaelis says. The percentage of patients with any given driver mutation is different in any of the 3 types of MPNs—polycythemia vera, essential thrombocythemia (ET), and myelofibrosis. Ever since the first mutation was described, questions have been asked as to why some patients act one way while others act another.

One of the factors that describes a patient’s later risk is the presence of a JAK2 mutation, Michaelis explains. Treatment is being changed based on the presence of JAK2, especially in ET. Decision-making for the treatment of these patients is much different now than it was 2 or 3 years again, says Michaelis, which she attributes to the understanding of the JAK2 mutation.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x